phenytoin has been researched along with ticlopidine in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (40.91) | 18.2507 |
| 2000's | 3 (13.64) | 29.6817 |
| 2010's | 9 (40.91) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Bryan, G; Rindone, JP | 1 |
| Eubanks, LE; Galen, W; McBurney, EI; Reed, R | 1 |
| Albani, F; Baruzzi, A; Cerullo, A; Riva, R | 1 |
| Privitera, M; Welty, TE | 1 |
| Abernethy, DR; Donahue, SR; Flockhart, DA; Ko, JW | 1 |
| López-Ariztegui, N; Martín, M; Nevado, C; Ochoà, M; Sánchez-Migallón, MJ | 1 |
| Klaassen, SL | 1 |
| Fitzgerald, DJ; Quinn, MJ | 1 |
| Abernethy, DR; Donahue, S; Flockhart, DA | 1 |
| Giancarlo, GM; Granda, BW; Greenblatt, DJ; Venkatakrishnan, K; von Moltke, LL | 1 |
| Brørs, O; Dahm, AE | 1 |
5 review(s) available for phenytoin and ticlopidine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Linear scleroderma in children.
Topics: Administration, Topical; Adolescent; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Betamethasone; Child; Dermatologic Agents; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Male; Methylprednisolone; Penicillins; Phenytoin; Scleroderma, Localized; Ticlopidine; Vitamin E | 1996 |
[Acute phenytoin poisoning secondary to an interaction with ticlopidine].
Topics: Acute Disease; Aged; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Ataxia; Cerebrovascular Disorders; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Epilepsies, Partial; Hematoma; Humans; Inactivation, Metabolic; Male; Mixed Function Oxygenases; Nausea; Phenytoin; Platelet Aggregation Inhibitors; Ticlopidine; Vertebrobasilar Insufficiency | 1998 |
Ticlopidine-induced phenytoin toxicity.
Topics: Aged; Anticonvulsants; Dose-Response Relationship, Drug; Drug Interactions; Humans; Male; Phenytoin; Platelet Aggregation Inhibitors; Ticlopidine | 1998 |
Ticlopidine and clopidogrel.
Topics: Adenosine Diphosphate; Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Angina, Unstable; Aspirin; Bone Marrow Diseases; Carbamazepine; Cardiovascular Diseases; Clopidogrel; Combined Modality Therapy; Coronary Disease; Drug Interactions; Hemorrhage; Humans; Myocardial Infarction; Peripheral Vascular Diseases; Phenytoin; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Safety; Stents; Theophylline; Thrombolytic Therapy; Ticlopidine | 1999 |
17 other study(ies) available for phenytoin and ticlopidine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
Topics: Glutathione; Pharmacology; Sulfur Radioisotopes | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Phenytoin toxicity associated with ticlopidine administration.
Topics: Aged; Drug Interactions; Fibrinolytic Agents; Humans; Ischemic Attack, Transient; Male; Phenytoin; Ticlopidine | 1996 |
Ticlopidine impairs phenytoin clearance: a case report.
Topics: Aged; Drug Interactions; Epilepsy, Complex Partial; Humans; Male; Phenytoin; Ticlopidine | 1996 |
Acute phenytoin toxicity followed by seizure breakthrough from a ticlopidine-phenytoin interaction.
Topics: Drug Interactions; Epilepsy, Complex Partial; Humans; Male; Middle Aged; Phenytoin; Ticlopidine; Time Factors | 1996 |
Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19.
Topics: Adult; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme Inhibitors; Humans; Male; Mixed Function Oxygenases; Phenytoin; Platelet Aggregation Inhibitors; Ticlopidine | 1997 |
Ticlopidine inhibits phenytoin clearance.
Topics: Administration, Oral; Adult; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme Inhibitors; Female; Fibrinolytic Agents; Humans; Male; Microsomes, Liver; Middle Aged; Mixed Function Oxygenases; Phenytoin; Ticlopidine | 1999 |
Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine.
Topics: Anti-Infective Agents; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Fibrinolytic Agents; Humans; Hydroxylation; Microsomes, Liver; Mixed Function Oxygenases; Omeprazole; Phenytoin; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Sulfaphenazole; Ticlopidine | 2001 |
[Phenytoin poisoning caused by interaction with ticlopidine].
Topics: Anticonvulsants; Brain Diseases; Drug Interactions; Epilepsy, Tonic-Clonic; Fibrinolytic Agents; Humans; Male; Middle Aged; Phenytoin; Ticlopidine | 2002 |